Menopausal hormone therapy: is there evidence for cardiac protection?.
Menopausal hormone therapy currently has no evidence-based role in the primary or secondary prevention of cardiovascular disease in women. Repeat analysis of the observational data that corrected for socioeconomic status, educational level, and coronary risk factors; as well as information from randomized clinical trials of menopausal hormone therapy both for healthy women and for women with established coronary heart disease and stroke support this statement. This approach is corroborated by recommendations from the US Food and Drug Administration and the recently released Guidelines for Cardiovascular Prevention for Women of the American Heart Association. The latter Guidelines display the lifestyle and pharmacologic interventions that are appropriate for cardiovascular disease risk reduction for women.
Wenger
Nanette K
NK
Division of Cardiology, Emory University School of Medicine, USA
D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004348:Drug Labeling; D015914:Estrogen Replacement Therapy; D019317:Evidence-Based Medicine; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D011372:Progestins / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
D011372:Progestins